Revvity (RVTY), a key player in the bio-tech market, recently displayed a strong Q4 performance. With
Earnings Per Share (EPS) beating expectations at $0.78 and
revenue recorded at $729 million, the firm outperformed its competitors during a strong trading day. The firm sold a significant number of shares, with key figures including Joel S. Goldberg and Exchange Traded Concepts LLC unloading 15,170 and 3,502 shares respectively. Nevertheless, other entities like Oak Thistle LLC and Avanza Fonder AB purchased shares. Despite positive Q4 results,
Revvity predicts lower 2025 earnings, the company is anticipating
3%-5% organic growth in 2025 amid market stabilization. The firm was recently granted
FDA clearance for the First-Ever Automated Free Testosterone Test and has been able to set a stable quarterly dividend at $0.07 per share. In other news, the company sealed a partnership with Element Biosciences to revolutionize neonatal genetic testing and announced a major restructuring, planning to present their
strategic vision at the J.P. Morgan Healthcare Conference 2025.
Revvity RVTY News Analytics from Mon, 29 Jul 2024 07:00:00 GMT to Sun, 02 Feb 2025 00:06:13 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 1
